https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53815 Wed 28 Feb 2024 16:05:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54805 Wed 13 Mar 2024 14:36:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29365 Wed 10 Nov 2021 15:14:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31060 14 days) exposure to a PDA were compared to control infants without a PDA. Results: Thirty out of 189 infants had prolonged exposure to a PDA. The left heart remodeled to a larger and more spherical shape and thus significantly increased in volume. Most changes occurred in the first 4 weeks, plateaued, and then returned to control values. Systolic function and estimates of filling pressure increased and effective arterial elastance reduced with a PDA, however contractility was unchanged. Wall thickness increased after 4 weeks of increased volume exposure. Conclusion: The preterm PDA induces early and significant remodeling of the left heart. A compensated cardiac physiology was seen with preserved systolic function, suggesting adaptive rather than pathological remodeling changes with prolonged exposure to a PDA.]]> Wed 10 Nov 2021 15:14:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29955 Wed 09 Feb 2022 15:56:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46265 1.5 mm and <72 hours after birth were randomized to NSAIDs vs placebo. No open-label NSAID treatment was allowed in either arm, but all infants with PDA volume load received supportive management, including optimization of airway pressure, careful fluid management, and diuretics as needed. The pilot outcomes were recruitment rate and incidence of open-label treatment. Secondary clinical outcomes included chronic lung disease or death, the planned primary outcome for a future large trial. Results: Overall, 54% of the approached parents consented to participate in the study. The median recruitment rate was 3 infants per month, and a total of 72 infants were randomized. One patient in each arm received open-label treatment. PDA closure rates were 74% for the NSAIDs arm vs 30% for the placebo arm, but this was not associated with significant changes in clinical outcomes. Conclusions: This pilot trial showed that recruitment of more than one-half of eligible infants with a low incidence of open-label treatment is feasible. PDA closure rates and clinical outcomes were similar to those reported in previous PDA trials.]]> Tue 15 Nov 2022 08:57:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38193 Thu 26 Aug 2021 09:23:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31061 Thu 17 Feb 2022 09:27:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44135 Sat 08 Oct 2022 12:36:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40786 Mon 18 Jul 2022 16:07:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43044 Mon 12 Sep 2022 12:38:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42822 Mon 05 Sep 2022 11:49:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46160 Fri 11 Nov 2022 19:20:09 AEDT ]]>